Holen Sie sich die Stockscreener-App
3.76
2.34%
-0.09
Schlusskurs vom Vortag:
$3.85
Offen:
$3.82
24-Stunden-Volumen:
70,670
Relative Volume:
1.21
Marktkapitalisierung:
$2.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.59M
KGV:
-0.1548
EPS:
-24.29
Netto-Cashflow:
$-16.49M
1W Leistung:
-49.33%
1M Leistung:
-66.11%
6M Leistung:
-88.83%
1J Leistung:
-98.16%
1-Tages-Spanne:
$3.67
$3.92
1-Wochen-Bereich:
$3.21
$7.5098
52-Wochen-Spanne:
$3.21
$264.00
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Firmenname
Transcode Therapeutics Inc
Sektor
Branche
Telefon
857-301-6857
Adresse
6 LIBERTY SQUARE, BOSTON
Vergleichen Sie RNAZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
3.76 | 2.62M | 0 | -19.59M | -16.49M | -776.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Transcode Therapeutics Inc Aktie (RNAZ) Neueste Nachrichten
Analysts Issue Forecasts for RNAZ Q1 Earnings - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
H.C. Wainwright raises TransCode Therapeutics target following SRC go-ahead for Cohort 3 - Investing.com
Clinical Trials News Live Feed - StockTitan
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial - StreetInsider.com
TransCode advances to third patient group in cancer trial - Investing.com India
Dow Surges 150 Points, US Current Account Deficit Widens In Q3 - Benzinga
Transcode announces SRC approved third cohort in TTX-MC138 clinical trial - TipRanks
RNAZTransCode Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
TransCode's Cancer Drug TTX-MC138 Advances to Final Trial Phase with Promising Safety Data - StockTitan
Transcode Therapeutics stock hits 52-week low at $6.89 By Investing.com - Investing.com Canada
TransCode Therapeutics to execute 1-for-33 reverse stock split on Dec 4 - MSN
Janux, Vir stocks rally on positive data for Janux drug JANX007 - MSN
TransCode Therapeutics Raises $8M in Private Placement - TipRanks
Why TransCode Therapeutics (RNAZ) Stock Is Diving - Benzinga
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split - The Manila Times
TransCode Therapeutics Announces Reverse Stock Split - TipRanks
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Meet Nasdaq Requirements | RNAZ Stock News - StockTitan
TransCode Therapeutics announces $8M private offering - MSN
Transcode Therapeutics issues 21.2M shares at 37.7c in private placement - Yahoo Finance
TransCode secures $8 million in private placement - Investing.com India
TransCode secures $8 million in private placement By Investing.com - Investing.com Australia
TransCode Therapeutics, Inc. Announces $8 Million Private Placement - The Manila Times
TransCode Therapeutics Secures $8M Private Placement, Issues 21.2M Shares | RNAZ Stock News - StockTitan
TransCode Therapeutics, Inc. announced that it expects to receive $8 million in funding - Marketscreener.com
Transcode Therapeutics announces 1-for-33 reverse stock split - Yahoo Finance
TransCode Therapeutics approves reverse stock split By Investing.com - Investing.com South Africa
TransCode Therapeutics advances with stockholder approvals By Investing.com - Investing.com Canada
TransCode Therapeutics advances with stockholder approvals - Investing.com
TransCode Therapeutics approves reverse stock split - Investing.com
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Maintain Nasdaq Listing | RNAZ Stock News - StockTitan
NewAmsterdam Pharma Reports Promising Phase 3 Trial Results - Yahoo Finance
Galecto (NASDAQ:GLTO) Shares Down 5.3% – Should You Sell? - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Receives Buy Rating from HC Wainwright - Defense World
Craig Hallum Downgrades Sow Good (NASDAQ:SOWG) to Hold - Defense World
The Goldman Sachs Group Boosts Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $41.00 - Defense World
TScan Therapeutics (NASDAQ:TCRX) Earns “Buy” Rating from HC Wainwright - Defense World
Sow Good (NASDAQ:SOWG) Lowered to Neutral Rating by Roth Mkm - Defense World
Spero Therapeutics’ (SPRO) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
TransCode Therapeutics Inc (RNAZ) Quarterly 10-Q Report - Quartz
Transcode Therapeutics Reports Increased Losses Amid Funding Challenges - TipRanks
Transcode Therapeutics sends open letter to shareholders - TipRanks
TransCode Therapeutics Open Letter to Shareholders - The Manila Times
TransCode (RNAZ) Faces Delisting Risk, Seeks Shareholder Approval for Reverse Split | RNAZ Stock News - StockTitan
Fluor Stock Tanks on Earnings Miss. There’s Good Reason Not to Panic. - MSN
Beam stock rebounds as Leerink upgrades despite fatality in gene editing trial - MSN
TransCode Therapeutics maintains Nasdaq listing with conditions - Investing.com
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance - The Manila Times
TransCode Therapeutics maintains Nasdaq listing with conditions By Investing.com - Investing.com UK
TransCode (RNAZ) Maintains Nasdaq Listing Despite Reprimand Over Compliance Issues | RNAZ Stock News - StockTitan
Finanzdaten der Transcode Therapeutics Inc-Aktie (RNAZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):